For the purposes of this question, “released” means that sufficient information is publicly available to essentially reproduce results in the white paper published by Isomorphic Labs on October 31, 2023 and to extend this to equivalent predictions: https://www.isomorphiclabs.com/articles/a-glimpse-of-the-next-generation-of-alphafold
This will resolve “YES” even if free-of-charge use is limited to non-commercial use, requires some form of user registration, and/or requires using an online service (no local execution) with a modest limit on prediction rate.
A non-commercial server with limited capability (such as restrictions on ligands) does not count as "released" in my opinion. Hundreds of papers have used the downloaded AlphaFold2 and AlphaFold-Multimer code to develop new pipelines and benchmark them and apply them in a high throughput manner to protein-protein interactions, antibodies, kinases and GPCRs in different states, etc. None of that will be available for AlphaFold3 is DeepMind/Isomorphic Labs don't release the code to non-commercial users.
@RolandDunbrack While I agree on the principle, for the purposes of this question I went with something I considered about 50/50 likely at the time I wrote the question. That was before I'd heard about the Eli Lilly and Novartis deals, so now I figure that if I participated in my own market I would buy below 50% and I would buy at about 50% if the date was extended to the end of 2024.
FYI, although it’s hard to see how this can be subjective, I will not participate in the market. Also FWIW I’m not sure which way I would bet if I did. I hope this resolves YES since the product is immediately useful for useful science.
Edit: I was also away from the news and posed this question before reading about Isomorphic Labs’ deals with Eli Lilly and Novartis.